[
  {
    "ts": "2025-09-02T23:30:00+00:00",
    "headline": "Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status",
    "summary": "LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai ha",
    "url": "https://finance.yahoo.com/news/eisai-initiated-rolling-supplemental-biologics-233000695.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "152f1be7-6eb1-3389-8053-78dfebd1fcad",
      "content": {
        "id": "152f1be7-6eb1-3389-8053-78dfebd1fcad",
        "contentType": "STORY",
        "title": "Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status",
        "description": "",
        "summary": "LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai ha",
        "pubDate": "2025-09-02T23:30:00Z",
        "displayTime": "2025-09-02T23:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eisai-initiated-rolling-supplemental-biologics-233000695.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eisai-initiated-rolling-supplemental-biologics-233000695.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "4523.T"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-02T20:44:45+00:00",
    "headline": "US Equity Indexes Decline as Gains in Treasury Yields Push Mag-7 Lower",
    "summary": "US equity indexes retreated Tuesday as the so-called Magnificent-7 stocks declined amid gains in gov",
    "url": "https://finance.yahoo.com/news/us-equity-indexes-decline-gains-204445256.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "607df1a8-f102-3c8f-a5cf-88b3c545016d",
      "content": {
        "id": "607df1a8-f102-3c8f-a5cf-88b3c545016d",
        "contentType": "STORY",
        "title": "US Equity Indexes Decline as Gains in Treasury Yields Push Mag-7 Lower",
        "description": "",
        "summary": "US equity indexes retreated Tuesday as the so-called Magnificent-7 stocks declined amid gains in gov",
        "pubDate": "2025-09-02T20:44:45Z",
        "displayTime": "2025-09-02T20:44:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/us-equity-indexes-decline-gains-204445256.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/us-equity-indexes-decline-gains-204445256.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^DJI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-02T20:02:12+00:00",
    "headline": "US Equity Markets End Lower Following Court Ruling Against Trump Tariffs",
    "summary": "US benchmark equity indexes ended lower on Tuesday as investors considered the impacts of a federal",
    "url": "https://finance.yahoo.com/news/us-equity-markets-end-lower-200212232.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "29727c93-d535-3df6-b564-bc04f48fa846",
      "content": {
        "id": "29727c93-d535-3df6-b564-bc04f48fa846",
        "contentType": "STORY",
        "title": "US Equity Markets End Lower Following Court Ruling Against Trump Tariffs",
        "description": "",
        "summary": "US benchmark equity indexes ended lower on Tuesday as investors considered the impacts of a federal",
        "pubDate": "2025-09-02T20:02:12Z",
        "displayTime": "2025-09-02T20:02:12Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/us-equity-markets-end-lower-200212232.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/us-equity-markets-end-lower-200212232.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": null,
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-02T19:58:00+00:00",
    "headline": "/U P D A T E -- Eisai Inc./",
    "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIKTM, pronounced \"I Click\") for maintenance dosing. LEQEMBI IQLIK is a subcutaneous autoinjector (SC-AI) developed by Ei",
    "url": "https://finance.yahoo.com/news/u-p-d-t-e-195800741.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "4e605d5b-9e43-36ae-b0b9-1cd3e641d542",
      "content": {
        "id": "4e605d5b-9e43-36ae-b0b9-1cd3e641d542",
        "contentType": "STORY",
        "title": "/U P D A T E -- Eisai Inc./",
        "description": "",
        "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIKTM, pronounced \"I Click\") for maintenance dosing. LEQEMBI IQLIK is a subcutaneous autoinjector (SC-AI) developed by Ei",
        "pubDate": "2025-09-02T19:58:00Z",
        "displayTime": "2025-09-02T19:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15",
          "originalWidth": 400,
          "originalHeight": 112,
          "caption": "Eisai logo and Biogen logo (PRNewsfoto/Eisai Co., Ltd.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bJrlns2nzwpK84mfnZzsTg--~B/aD0xMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15.cf.webp",
              "width": 400,
              "height": 112,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lpiHqXXYlwJmL4_lRc2Yvw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/u-p-d-t-e-195800741.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/u-p-d-t-e-195800741.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ESAIY"
            },
            {
              "symbol": "ESALF"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "4523.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-02T19:35:38+00:00",
    "headline": "Biogen (BIIB) Stock Is Up, What You Need To Know",
    "summary": "Shares of biotech company Biogen (NASDAQ:BIIB) jumped 4.8% in the afternoon session after the company and its partner Eisai received FDA approval for a weekly subcutaneous injection of their Alzheimer's drug, Leqembi, for maintenance dosing.",
    "url": "https://finance.yahoo.com/news/biogen-biib-stock-know-193538936.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "e45b703d-e957-3610-97db-6bf20253385e",
      "content": {
        "id": "e45b703d-e957-3610-97db-6bf20253385e",
        "contentType": "STORY",
        "title": "Biogen (BIIB) Stock Is Up, What You Need To Know",
        "description": "",
        "summary": "Shares of biotech company Biogen (NASDAQ:BIIB) jumped 4.8% in the afternoon session after the company and its partner Eisai received FDA approval for a weekly subcutaneous injection of their Alzheimer's drug, Leqembi, for maintenance dosing.",
        "pubDate": "2025-09-02T19:35:38Z",
        "displayTime": "2025-09-02T19:35:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "BIIB Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RI16PwyrPkPhFQpSFVHcpw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IR.mhpWSH09RyIH1vck_EQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-biib-stock-know-193538936.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-biib-stock-know-193538936.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "4523.T"
            },
            {
              "symbol": "STOK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-02T17:27:06+00:00",
    "headline": "US Equity Indexes Slump, Volatility Spikes Amid Gains in Treasury Yields",
    "summary": "US equity indexes headed lower after midday on Tuesday amid a sharp move higher in government bond y",
    "url": "https://finance.yahoo.com/news/us-equity-indexes-slump-volatility-172706246.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "f1c89fd3-dbd2-38d3-9372-635930506ba4",
      "content": {
        "id": "f1c89fd3-dbd2-38d3-9372-635930506ba4",
        "contentType": "STORY",
        "title": "US Equity Indexes Slump, Volatility Spikes Amid Gains in Treasury Yields",
        "description": "",
        "summary": "US equity indexes headed lower after midday on Tuesday amid a sharp move higher in government bond y",
        "pubDate": "2025-09-02T17:27:06Z",
        "displayTime": "2025-09-02T17:27:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/us-equity-indexes-slump-volatility-172706246.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/us-equity-indexes-slump-volatility-172706246.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GC=F"
            },
            {
              "symbol": "DX-Y.NYB"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^VIX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-02T13:00:00+00:00",
    "headline": "Grand River Aseptic Manufacturing (GRAM) Appoints Denis Johnson as Chief Executive Officer",
    "summary": "Effective September 1, 2025 Denis Johnson, CEO Denis Johnson, CEO, Grand River Aseptic Manufacturing Grand Rapids, Michigan, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Grand River Aseptic Manufacturing (“GRAM” or the “Company”), a portfolio company of Arlington Capital Partners, today announced the promotion of Denis Johnson to Chief Executive Officer, effective September 1, 2025. Mr. Johnson has served as President of GRAM since March 31, 2025. In this new role, Mr. Johnson will lead GRAM’s next phase",
    "url": "https://finance.yahoo.com/news/grand-river-aseptic-manufacturing-gram-130000683.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "2ba65e64-700b-35cb-9e86-07c1fcc38cd3",
      "content": {
        "id": "2ba65e64-700b-35cb-9e86-07c1fcc38cd3",
        "contentType": "STORY",
        "title": "Grand River Aseptic Manufacturing (GRAM) Appoints Denis Johnson as Chief Executive Officer",
        "description": "",
        "summary": "Effective September 1, 2025 Denis Johnson, CEO Denis Johnson, CEO, Grand River Aseptic Manufacturing Grand Rapids, Michigan, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Grand River Aseptic Manufacturing (“GRAM” or the “Company”), a portfolio company of Arlington Capital Partners, today announced the promotion of Denis Johnson to Chief Executive Officer, effective September 1, 2025. Mr. Johnson has served as President of GRAM since March 31, 2025. In this new role, Mr. Johnson will lead GRAM’s next phase",
        "pubDate": "2025-09-02T13:00:00Z",
        "displayTime": "2025-09-02T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/1f612fc1cdd39cff0d9d6a73fa0c6ec3",
          "originalWidth": 2400,
          "originalHeight": 2000,
          "caption": "Denis Johnson, CEO, Grand River Aseptic Manufacturing",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6pgKNF87coLGeP5M3hg_Zw--~B/aD0yMDAwO3c9MjQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/1f612fc1cdd39cff0d9d6a73fa0c6ec3.cf.webp",
              "width": 2400,
              "height": 2000,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sYfrao2Nth6kecZUzR76CQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/1f612fc1cdd39cff0d9d6a73fa0c6ec3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/grand-river-aseptic-manufacturing-gram-130000683.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/grand-river-aseptic-manufacturing-gram-130000683.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "BSX"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-02T12:20:00+00:00",
    "headline": "Amgen to invest $600M in new US center; Sanofi drug for ITP approved",
    "summary": "The new \"science and innovation center\" will be built at Amgen's headquarters in Thousand Oaks, California. Elsewhere, Wayrilz became the first BTK blocker cleared for immune thrombocytopenia.",
    "url": "https://www.biopharmadive.com/news/amgen-new-center-replimune-fda-meeting-sanofi-wayrilz/758944/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "647688de-b04a-3193-acb4-442443f2a424",
      "content": {
        "id": "647688de-b04a-3193-acb4-442443f2a424",
        "contentType": "STORY",
        "title": "Amgen to invest $600M in new US center; Sanofi drug for ITP approved",
        "description": "",
        "summary": "The new \"science and innovation center\" will be built at Amgen's headquarters in Thousand Oaks, California. Elsewhere, Wayrilz became the first BTK blocker cleared for immune thrombocytopenia.",
        "pubDate": "2025-09-02T12:20:00Z",
        "displayTime": "2025-09-02T12:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/amgen-new-center-replimune-fda-meeting-sanofi-wayrilz/758944/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-invest-600m-us-center-122000099.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "ROG.SW"
            },
            {
              "symbol": "4523.T"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-02T11:00:00+00:00",
    "headline": "Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome",
    "summary": "BEDFORD, Mass. & CAMBRIDGE, Mass., September 02, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced data from Phase 1/2a and open-label extension (OLE) studies of zorevunersen that support the potential for zorevunersen to be the first disease-modifying medicine for Dravet syndrome. Findings were presented at the 36th International Ep",
    "url": "https://finance.yahoo.com/news/stoke-therapeutics-biogen-present-data-110000754.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "f5eb75d1-a8b2-31b9-ad13-665f006d35d9",
      "content": {
        "id": "f5eb75d1-a8b2-31b9-ad13-665f006d35d9",
        "contentType": "STORY",
        "title": "Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome",
        "description": "",
        "summary": "BEDFORD, Mass. & CAMBRIDGE, Mass., September 02, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced data from Phase 1/2a and open-label extension (OLE) studies of zorevunersen that support the potential for zorevunersen to be the first disease-modifying medicine for Dravet syndrome. Findings were presented at the 36th International Ep",
        "pubDate": "2025-09-02T11:00:00Z",
        "displayTime": "2025-09-02T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/58dfaf097acb244f172066981a5d0061",
          "originalWidth": 480,
          "originalHeight": 223,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GznYIamahs28VjKfFYKGJA--~B/aD0yMjM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/58dfaf097acb244f172066981a5d0061.cf.webp",
              "width": 480,
              "height": 223,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AU5P2y5TBI9N7afyla80Bw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/58dfaf097acb244f172066981a5d0061.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/stoke-therapeutics-biogen-present-data-110000754.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stoke-therapeutics-biogen-present-data-110000754.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "STOK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-02T11:00:00+00:00",
    "headline": "Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome",
    "summary": "– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies – – Substantial increase in seizure-free days and continuous improvements in quality of life demonstrated in patients already taking standard of care anti-seizure medicines – – Zorevunersen generally well tolerated across all studies – – Data support pivotal Phase 3 EMPEROR study now underway – CAMBRIDGE, Mass",
    "url": "https://finance.yahoo.com/news/biogen-stoke-therapeutics-present-data-110000512.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "56a45926-28e8-3601-81ff-3424d7ca0304",
      "content": {
        "id": "56a45926-28e8-3601-81ff-3424d7ca0304",
        "contentType": "STORY",
        "title": "Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome",
        "description": "",
        "summary": "– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies – – Substantial increase in seizure-free days and continuous improvements in quality of life demonstrated in patients already taking standard of care anti-seizure medicines – – Zorevunersen generally well tolerated across all studies – – Data support pivotal Phase 3 EMPEROR study now underway – CAMBRIDGE, Mass",
        "pubDate": "2025-09-02T11:00:00Z",
        "displayTime": "2025-09-02T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-stoke-therapeutics-present-data-110000512.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-stoke-therapeutics-present-data-110000512.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "STOK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-02T07:30:08+00:00",
    "headline": "Biogen Inc. (BIIB)’s Alzheimer’s Drug Leqembi Wins EU Nod, Now Approved in 48 Countries",
    "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Biogen Inc. is one of them. Biogen Inc. (NASDAQ:BIIB), founded in 1978 and headquartered in Cambridge, Massachusetts, continues to strengthen its leadership in neurological disorders, with a particular focus on Alzheimer’s disease. It stands tenth on our list […]",
    "url": "https://finance.yahoo.com/news/biogen-inc-biib-alzheimer-drug-073008417.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "101dcfe2-32e1-31e9-b85b-542d3f4c84e0",
      "content": {
        "id": "101dcfe2-32e1-31e9-b85b-542d3f4c84e0",
        "contentType": "STORY",
        "title": "Biogen Inc. (BIIB)’s Alzheimer’s Drug Leqembi Wins EU Nod, Now Approved in 48 Countries",
        "description": "",
        "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Biogen Inc. is one of them. Biogen Inc. (NASDAQ:BIIB), founded in 1978 and headquartered in Cambridge, Massachusetts, continues to strengthen its leadership in neurological disorders, with a particular focus on Alzheimer’s disease. It stands tenth on our list […]",
        "pubDate": "2025-09-02T07:30:08Z",
        "displayTime": "2025-09-02T07:30:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/e2283f654b2aa1a9b033871d1749bb3e",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Biogen Inc. (BIIB)’s Alzheimer’s Drug Leqembi Wins EU Nod, Now Approved in 48 Countries",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BIsNYxkkSkZw9H7iY4_90Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/e2283f654b2aa1a9b033871d1749bb3e.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8JF8zBYqEJabkz9LuHvmTg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/e2283f654b2aa1a9b033871d1749bb3e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-inc-biib-alzheimer-drug-073008417.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-inc-biib-alzheimer-drug-073008417.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "4523.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-02T06:30:00+00:00",
    "headline": "Startup Corsera Health aims to bring preventive heart medicine to the masses",
    "summary": "Co-founded by RNA interference pioneer John Maraganore and former Medicines Company head Clive Meanwell, Corsera Health is developing diagnostic tools and medicines for heart health.",
    "url": "https://www.biopharmadive.com/news/corsera-health-maraganore-meanwell-startup-launch/758642/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "a8c9adab-1442-31e7-b799-ddfb48e23948",
      "content": {
        "id": "a8c9adab-1442-31e7-b799-ddfb48e23948",
        "contentType": "STORY",
        "title": "Startup Corsera Health aims to bring preventive heart medicine to the masses",
        "description": "",
        "summary": "Co-founded by RNA interference pioneer John Maraganore and former Medicines Company head Clive Meanwell, Corsera Health is developing diagnostic tools and medicines for heart health.",
        "pubDate": "2025-09-02T06:30:00Z",
        "displayTime": "2025-09-02T06:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "BioPharma Dive, an Industry Dive publication",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U3g5.ulK0vcCqcdyFlYvVw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DH6ljKWVk5FO27mUzvHUcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/corsera-health-maraganore-meanwell-startup-launch/758642/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/startup-corsera-health-aims-bring-063000864.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALNY"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]